Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of RVT-101 versus placebo added to donepezil in mild to moderate Alzheimer's disease
2015-002957-37Phase 3Completed
- Sponsor
- Sio Gene Therapies
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing RVT-101 + donepezil with Placebo + donepezil (2 arms). Primary endpoint: ADAS-Cog-11 score change from baseline to Week 24. Started Nov 2015; status: completed.
02
Drugs
intepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2015-002957-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002957-37.